| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) |
|
11845.30 | 107.40 | 0.91% |
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
iBio, Inc. (AMEX: IBIO)
IBIO Technical Analysis
4
| As on 31st Oct 2017 IBIO Share Price closed @ 0.30 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.37 & Sell for SHORT-TERM with Stoploss of 0.31 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IBIO Share Price
| Open | 0.31 | Change | Price | % |
| High | 0.31 | 1 Day | -0.01 | -3.23 |
| Low | 0.30 | 1 Week | 0.00 | 0.00 |
| Close | 0.30 | 1 Month | 0.00 | 0.00 |
| Volume | 186287 | 1 Year | -0.16 | -34.78 |
| 52 Week High 0.56 | 52 Week Low 0.26 | ||||
AMEX USA Most Active Stocks
| PAL | 0.05 | -50.00% |
| NGD | 3.29 | -6.80% |
| RBY | 0.03 | -70.00% |
| LODE | 0.12 | -7.69% |
| PBTH | 8.23 | 0.37% |
| GGR | 0.02 | 100.00% |
| VTG | 0.05 | -16.67% |
| SYRG | 8.13 | 0.87% |
| GSX | 0.02 | 0.00% |
| SHZ | 0.10 | -16.67% |
AMEX USA Top Gainers Stocks
AMEX USA Top Losers Stocks
| IBIO Daily Charts |
IBIO Intraday Charts |
Whats New @ Bazaartrend |
IBIO Free Analysis |
|
|
IBIO Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 0.31 |
| RESISTANCE | 0.31 |
| SUPPORT | 0.29 |
| SUPPORT | 0.29 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
IBIO Target for Month May
| 4th UP TARGET | 0.49 |
| 3rd UP TARGET | 0.43 |
| 2nd UP TARGET | 0.39 |
| 1st UP TARGET | 0.35 |
| 1st DOWN TARGET | 0.25 |
| 2nd DOWN TARGET | 0.21 |
| 3rd DOWN TARGET | 0.17 |
| 4th DOWN TARGET | 0.11 |
IBIO Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
IBIO Target for Year 2019
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
iBio, Inc. ( AMEX USA Symbol : IBIO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IBIO Other Details
| Segment | EQ | |
| Market Capital | 43945728.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | http://www.ibioinc.com | |
IBIO Address
 |
9 Innovation Way Suite 100 Newark, DE 19711 United States Phone: 302-355-0650 |
|
IBIO Latest News
IBIO Business Profile
iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies include iBioLaunch, a transformative platform technology for the development and production of biologics; and iBioModulator, a technology platform that improves the potency and duration of the effect of prophylactic and therapeutic vaccines. The companyÂ’s product candidates include C1 Esterase Inhibitor, a preclinical stage plasma-derived protein; Alpha-Galactosidase, a preclinical orphan designation stage enzyme replacement; and Palivizumab, a preclinical stage monoclonal antibody for the therapeutic protein market. Its product candidates also comprise H1N1 Influenza and H5N1 Influenza viral disease vaccines that completed Phase I; Hookworm parasitic pathogen vaccine, which is in preclinical stage; and Human Papillomavirus therapeutic vaccine that is in preclinical stage. In addition, the companyÂ’s product candidates include Anthrax/Plague bacterial disease vaccine that is in preclinical stage; and Anthrax monoclonal antibody that is in preclinical stage for the Biodefense market. It has a collaboration agreement with Fraunhofer Center for Molecular Biology to perform research and development activities to develop the recombinant form of C1 esterase inhibitor; an alliance with GE Healthcare to commercialize its plant-based technologies for the manufacture of biopharmaceuticals and vaccines; a collaboration agreement granting FioCruz/Bio-Manguinhos a license to use its proprietary technology in connection with the development, manufacture, and commercialization of vaccine products; and a license and collaboration agreement enabling Caliber Biotherapeutics LLC to use its iBioLaunch platform in connection with the development of an undisclosed monoclonal antibody-based therapeutic protein for an oncology indication. The company is headquartered in Newark, Delaware.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service